GAMMA Investing LLC lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 2,299.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,759 shares of the company's stock after purchasing an additional 8,394 shares during the quarter. GAMMA Investing LLC's holdings in LivaNova were worth $344,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of LIVN. Rhumbline Advisers grew its holdings in shares of LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after purchasing an additional 899 shares in the last quarter. Principal Financial Group Inc. boosted its stake in LivaNova by 2.6% in the fourth quarter. Principal Financial Group Inc. now owns 175,878 shares of the company's stock worth $8,145,000 after buying an additional 4,476 shares in the last quarter. New York State Common Retirement Fund boosted its stake in LivaNova by 122.8% in the fourth quarter. New York State Common Retirement Fund now owns 37,557 shares of the company's stock worth $1,739,000 after buying an additional 20,699 shares in the last quarter. Handelsbanken Fonder AB grew its position in LivaNova by 12.1% during the fourth quarter. Handelsbanken Fonder AB now owns 17,637 shares of the company's stock valued at $817,000 after acquiring an additional 1,900 shares during the last quarter. Finally, Amalgamated Bank grew its position in LivaNova by 3.0% during the fourth quarter. Amalgamated Bank now owns 24,900 shares of the company's stock valued at $1,153,000 after acquiring an additional 729 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Wall Street Analysts Forecast Growth
LIVN has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Robert W. Baird increased their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Stifel Nicolaus reduced their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Finally, Wall Street Zen cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of "Buy" and an average price target of $59.29.
Read Our Latest Stock Report on LIVN
LivaNova Trading Up 0.8%
Shares of NASDAQ:LIVN traded up $0.34 during trading on Friday, reaching $45.51. 910,276 shares of the company traded hands, compared to its average volume of 643,707. The firm has a market capitalization of $2.48 billion, a price-to-earnings ratio of -11.13 and a beta of 0.90. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $57.35. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The business's fifty day moving average is $41.63 and its 200-day moving average is $43.62.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
